Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

References

• Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2002:162–192.
   PubMedGoogle Scholar
• Béné MC, Kolopp Sarda MN, El KaissouniJ, De March Kennel A, Molé C, Kohler C, Faure GC. Automated cell count in flow cytometry: a valuable tool to assess CD4 absolute levels in peripheral blood. Am J Clin Pathol 1998;110:321–26.
   PubMed Web of Science ®Google Scholar
• Borowitz M, Chan J. B lymphoblastic leukaemia/lymphoma, not otherwise specified. WHO classification of tumours of hematopoietic and lymphoid tissuesIn: Swerdlow S, Campo E, Harris NL, et al. , editors. Lyon: IARC; 2008. 168–170.
   Google Scholar
• Gokbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2006;19:701–713.
   PubMed Web of Science ®Google Scholar
• Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39:12–19.
   PubMed Web of Science ®Google Scholar
• Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16:1233–1258.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009;23:806–807.
   PubMed Web of Science ®Google Scholar
• Borowitz M, Chan J. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. WHO classification of tumours of hematopoietic and lymphoid tissuesIn: Swerdlow S, Campo E, Harris NL, et al., editors. Lyon: IARC; 2008. 171–175.
   Google Scholar
• Borowitz M, Chan J. T lymphoblastic leukaemia/lymphoma. In: WHO classification of tumours of hematopoietic and lymphoid tissuesSwerdlow S, Campo E, Harris NL, et al. , editors. Lyon: IARC; 2008. 176–178.
   Google Scholar
• Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880–3889.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007;110:1178–1186.
   PubMed Web of Science ®Google Scholar
• Golay J, Di Gaetano N, Amico D, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005;128:310–317.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leuk Lymphoma 2004;45:731–733.
   PubMed Web of Science ®Google Scholar
• Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004;18:1557–1558.
   Google Scholar
• Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50:886–891.
   PubMed Web of Science ®Google Scholar
• d'Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465–473.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006;132:398–409.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol 2008;88:209–211.
   PubMed Web of Science ®Google Scholar
• Cheung KC, Wong LG, Yeung YM. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg. Leuk Lymphoma 2008;49:596–597.
   PubMed Web of Science ®Google Scholar
• Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010 Sep 15. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar